Compare LQDA & ALK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | ALK |
|---|---|---|
| Founded | 2004 | 1932 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.1B |
| IPO Year | 2020 | 2003 |
| Metric | LQDA | ALK |
|---|---|---|
| Price | $78.03 | $53.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | $41.00 | ★ $62.92 |
| AVG Volume (30 Days) | 2.4M | ★ 3.2M |
| Earning Date | 05-08-2026 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.81 | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | $158,320,000.00 | ★ $10,426,000,000.00 |
| Revenue This Year | $278.87 | $11.19 |
| Revenue Next Year | $57.13 | $5.11 |
| P/E Ratio | $147.92 | ★ N/A |
| Revenue Growth | ★ 1031.18 | 8.09 |
| 52 Week Low | $11.85 | $33.03 |
| 52 Week High | $78.25 | $65.35 |
| Indicator | LQDA | ALK |
|---|---|---|
| Relative Strength Index (RSI) | 75.44 | 70.09 |
| Support Level | $31.23 | $36.64 |
| Resistance Level | N/A | $56.43 |
| Average True Range (ATR) | 4.14 | 2.41 |
| MACD | 0.40 | 0.60 |
| Stochastic Oscillator | 91.55 | 90.94 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Alaska Air Group Inc operates two airlines, Alaska and Horizon, in three operating segments. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo throughout the U.S., and in parts of Mexico and Costa Rica. The Regional segment includes Horizon's and other third-party carriers' scheduled air transportation for passengers across a shorter distance network within the U.S. and Canada under capacity purchase agreements. The Hawaiian Airlines segment includes scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. It earns revenues from Passenger tickets, including ticket breakage and net of taxes and fees, Passenger ancillary, and Mileage Plan passenger revenue.